Pfizer Inc. $PFE Stock Bought by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,689,911 shares of the biopharmaceutical company’s stock after acquiring an additional 32,500 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Pfizer were worth $48,196,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Heartland Consultants Inc. increased its stake in Pfizer by 26.9% during the third quarter. First Heartland Consultants Inc. now owns 16,288 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 3,454 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Pfizer by 25.2% in the 3rd quarter. GAMMA Investing LLC now owns 107,263 shares of the biopharmaceutical company’s stock valued at $3,059,000 after purchasing an additional 21,561 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Pfizer by 38.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 545,850 shares of the biopharmaceutical company’s stock valued at $15,568,000 after purchasing an additional 150,553 shares during the last quarter. Atwood & Palmer Inc. grew its holdings in shares of Pfizer by 63.8% during the 3rd quarter. Atwood & Palmer Inc. now owns 16,261 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 6,332 shares during the period. Finally, Apella Capital LLC grew its holdings in shares of Pfizer by 22.2% during the 3rd quarter. Apella Capital LLC now owns 56,927 shares of the biopharmaceutical company’s stock worth $1,594,000 after purchasing an additional 10,327 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Cantor Fitzgerald upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.61.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA expands TUKYSA opportunity: The FDA approved TUKYSA (tucatinib) with trastuzumab and pertuzumab as a frontline maintenance treatment for adults with unresectable or metastatic HER2-positive breast cancer. The expanded label moves the drug into an earlier treatment setting, potentially increasing its addressable market and supporting Pfizer’s oncology growth. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Promising pipeline developments: Positive Phase 3 results for LITFULO in nonsegmental vitiligo showed meaningful facial and total-body repigmentation with favorable tolerability. Pfizer plans regulatory submissions, which could broaden the drug’s immunology-market opportunity. Pfizer Posted Positive Phase 3 Vitiligo Results
• Positive Sentiment: Potential earnings support: Analysts note Pfizer’s history of earnings surprises and suggest the company currently has favorable conditions for another quarterly beat. Oncology product sales, biosimilars, and late-stage pipeline progress will be important ahead of third-quarter results. Will Pfizer Beat Estimates Again?
• Neutral Sentiment: Analyst target increase: Cantor Fitzgerald raised its price target from $27 to $28 while retaining a “neutral” rating, implying limited near-term upside and signaling that valuation and execution risks remain balanced. Cantor Fitzgerald Pfizer Price Target Update
• Negative Sentiment: Dividend and balance-sheet concerns: Pfizer declared a quarterly dividend of $0.43 per share, but commentary warns that the roughly 6% yield, frozen payout, debt, and a recent multibillion-dollar write-down may raise questions about long-term dividend reliability. Pfizer’s Yield and Dividend Risks
• Negative Sentiment: Restructuring and earnings pressure: Pfizer plans to cut about 330 jobs at its Sicily facility, while analysts describe an increasingly challenging period. The company’s cost reductions and recent loss per share underscore concerns about post-pandemic revenue declines and execution. Pfizer to Cut Around 330 Jobs in Italy

Pfizer Stock Down 0.6%

Shares of PFE opened at $27.82 on Friday. The stock has a market capitalization of $158.59 billion, a PE ratio of 36.61, a P/E/G ratio of 1.88 and a beta of 0.32. Pfizer Inc. has a 1 year low of $23.62 and a 1 year high of $29.21. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company’s 50-day simple moving average is $27.62 and its 200-day simple moving average is $26.49.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s payout ratio is 226.32%.

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.